Importantly, the well characterized PPARγ agonist rosiglitazone suppresses the ability of systemic UV-IS to suppress CHS responses as well as the ability of UVB treatment to promote B16F10 tumor growth [1]. This evidence concerns the gene LYST and neoplasm.